A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis.
Latest Information Update: 15 Feb 2022
At a glance
- Drugs Abatacept (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PsA-I
- Sponsors Bristol-Myers Squibb
- 08 Feb 2022 Results of post hoc analysis assessing implementation of OMERACT Psoriatic Arthritis MRI Scoring System in this study published in the Rheumatology
- 05 Oct 2021 According to Eudra the trial has been completed in France.
- 05 Jun 2021 Results of an analysis retrospectively assessing utilization of the Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) presented at the 22nd Annual Congress of the European League Against Rheumatism